Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Alkermes Strategy After Antidepressant Failures Doubted By Wall Street

This article was originally published in The Pink Sheet Daily

Executive Summary

With a pair of Phase III failures for its major depression disorder candidate ALKS-5461, Alkermes is pinning hopes on a third pivotal trial plus ad hoc analysis of a failed study – a strategy analysts find unlikely to prevail.


Related Content

Will Alkermes Data Package Support ALKS 5461 Approval?
Alkermes Says New Aripiprazole Is Just The Start Of A Blockbuster Streak


Related Companies